drugset / Trial / NCT07644650
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
Phase 1
Not yet recruiting
420 enrolled
Mabsoft Therapeutics (Shanghai) Co., Ltd.
Mabsoft Therapeutics (Australia) Pty. Ltd. · collabMabsoft Therapeutics (Guangdong Hengqin) Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.
Timeline
- Start
- 2026-06-15
- Primary completion
- 2028-06-30
- Completion
- 2030-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MST-168 | Unknown | — | — |